| Prognostic significance of interim (18)F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma. | |
| | |
MedLine Citation:
|
PMID: 21334197 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
PURPOSE: (18)F-fluoro-2-dexoy-d-glucose-positron emission tomography (FDG-PET)/computerised tomography (CT) has been used for staging and monitoring responses to treatment in patients with diffuse large B cell lymphoma (DLBCL). The sequential interim PET/CT was prospectively investigated to determine whether it provided additional prognostic information and could be a positive predictable value within patients with the same international prognostic index (IPI) after the use of rituximab in DLBCL. METHODS: One hundred and sixty-one patients with newly diagnosed DLBCL were enroled; the assessment of the PET/CT was performed at the time of diagnosis and mid-treatment of rituxibmab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP). RESULTS: Sixty-seven patients (41.6%) presented with advanced stage disease and 27 (16.8%) had bulky lesions. Forty-three patients (26.7%) continued to have positive metabolic uptakes with a significantly high relapse rate (62.8%) compared to the patients with a negative interim PET/CT (12.1%) (P<0.01). After a median follow-up of 30.8months, the positivity of interim PET/CT was found to be a prognostic factor for both overall survival (OS) and progression-free survival (PFS), with a hazard ratio of 4.07 (2.62-6.32) and 5.46 (3.49-8.52), respectively. In the low-risk IPI group, the 3-year OS and PFS rates were significantly different in the patients with positive (53.3% and 52.5%) and negative (93.8% and 88.3%) interim PET/CT, respectively (P<0.01). These significant prognostic differences of interim PET/CT responses were consistent with the results of the patients with high-risk IPI group (P<0.01). CONCLUSIONS: Interim PET/CT scanning had a significant predictive value for disease progression and survival of DLBCL in post-rituximab treatment; it might be the single most important determinant of clinical outcome in patients with the same IPI risk. |
| | |
Authors:
|
Deok-Hwan Yang; Jung-Joon Min; Ho-Chun Song; Yong Yeon Jeong; Woong-Ki Chung; Soo-Young Bae; Jae-Sook Ahn; Yeo-Kyeoung Kim; Hee-Seung Bom; Ik-Joo Chung; Hyeoung-Joon Kim; Je-Jung Lee |
Related Documents
:
|
10331767 - Delayed mr imaging of hepatocellular carcinoma enhanced by gadobenate dimeglumine (gd-b... 19033787 - Duodenal metastasis from hepatocelluar carcinoma demonstrated on fdg pet/ct imaging. 10510907 - Ct and mri findings of congestive hepatic infarction caused by tumor thrombus of hcc in... 16177427 - Hepatocellular carcinoma in the cirrhotic liver with helical ct and mri: imaging spectr... 22434697 - Tumor response assessments with diffusion and perfusion mri. 1710327 - Holocord astrocytoma--case report. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-2-17 |
Journal Detail:
|
Title: European journal of cancer (Oxford, England : 1990) Volume: - ISSN: 1879-0852 ISO Abbreviation: - Publication Date: 2011 Feb |
Date Detail:
|
Created Date: 2011-2-21 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9005373 Medline TA: Eur J Cancer Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Copyright Information:
|
Copyright © 2011 Elsevier Ltd. All rights reserved. |
Affiliation:
|
Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Jeollanam-do, Republic of Korea. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refracto...
Next Document: Anticancer effects of the p53 activator nutlin-3 in Ewing's sarcoma cells.